


G-TAC: GCIG - Targeted Agents in CxCa

GEICO Study design



1ºEnd-Point: PFS
2ºEnd-Points:

- OS
- Frequency and severity of adverse events (AEs)
- PRO

Stratification Factors

- **Histology**(squamous vs adenosquamous adenocarcinoma
- **FIGO Stage:** IB2, IIA2 or IIB w/ pelvic positive lymph nodes vs III/IVA vs any Stage with positive ParaAortic Lymph nodes
- **Response to Concurrent Chemo-Radiation:** Partial Response vs Complete Response by RECIST Criteria v1.1

***TSR-042:** is an anti-PD1 IgG4 humanized monoclonal antibody that binds with high affinity to PD-1. TSR-042 will be administered at fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for the remainder of the study.